Differential expression of follicular fluid cytokines: relationship to subsequent pregnancy in IVF cycles

Dr Mohamed Bedaiwy graduated from Assuit School of Medicine, Egypt in 1992, where he remains on the staff. His training in obstetrics and gynaecology has taken him to several institutions in USA, notably the Cleveland Clinic Foundation, Ohio. He became expert in reproductive biology and minimally invasive surgery. Currently he is engaged on a reproductive endocrinology and IVF fellowship at the University of Toronto, Canada. Dr Bedaiwy has published extensively and has been honoured with awards from the Society of Reproductive Surgeons (2001), the Pacific Coast Reproductive Society (Serono In-Training Award, 2002), and the ASRM (Best Video Award, 2001–2003). His special interests include endometriosis and ovarian tissue cryopreservation.

Mohamed Bedaiwy1,2, Ahmed Y Shahin2, Ahmed M AbulHassan2, Jeffrey M Goldberg1, Rakesh K Sharma1, Ashok Agarwal1, Tommaso Falcone1,3
1Reproductive Research Centre, Department of Obstetrics-Gynaecology and Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA; 2Department of Obstetrics and Gynaecology, Women’s Health Centre, Assiut University, Egypt.
3Correspondence: Tel: +216 444 1758; Fax: +216 445 5526; e-mail: falcont@ccf.org

Abstract

The objective of this study was to investigate the role of cytokines in the peri-ovulatory follicular fluid (FF) during IVF cycles. FF from 112 women was obtained during oocyte retrieval for IVF. The concentrations of five cytokines [interleukin (IL)-1β, IL-6, IL-12, IL-13, and tumour necrosis factor alpha (TNFα)] were measured in FF and their concentrations compared among women who became pregnant and those who did not. Thirty-one endometriosis patients, 15 idiopathic infertility, 21 tubal factor infertility, 15 ovarian factor infertility, and 30 patients with male factor infertility were included. Interleukin-13 and TNFα were absent in the peri-ovulatory FF of all patients. Fifty-two patients achieved pregnancy, whereas 60 did not. Both pregnant and non-pregnant groups were comparable for age, parity, ovarian stimulation parameters, fertilization rates, and embryo freezing rates. Concentrations of FF IL-1β were not significantly different between pregnant and non-pregnant cycles. Concentrations of FF IL-6 were significantly higher in pregnant compared with non-pregnant cycles (P = 0.0005). Concentrations of FF IL-12 were significantly lower in pregnant compared with non-pregnant cycles (P = 0.0002). Higher concentrations of IL-12 and lower concentrations of IL-6 in the peri-ovulatory FF are associated with a negative outcome in IVF treatment. Interleukins-12 and IL-6 are biological markers that appear to affect IVF outcome.

Keywords: cytokines, follicular fluid, pregnancy

Introduction

While the number and activity of polymorphonuclear leukocytes in fresh whole blood do not change significantly during the natural menstrual cycle, their number increases and their migration activity decreases during ovarian stimulation (Giuliani et al., 2004).

The migration of leukocytes during ovulation is limited to the peri-ovulatory follicles and corpus luteum (CL), suggesting hormonal control of leukocyte migration to these tissues. The pre-ovulatory follicular fluid (FF) possesses neutrophil chemotactic activity that is higher in conception than in non-conception cycles (Herriot et al., 1986). It has been shown that monocyte chemotactic protein 1 (MCP-1) concentrations in women with endometriosis are significantly lower compared with a control group with tubal infertility (Xu et al., 2006).

Individual cytokines in human ovarian FF play an important role in the follicular microenvironment and can be used as predictors for IVF outcome. Mean concentrations of interleukin (IL)-1 were lower in treatment attempts leading to a clinical pregnancy compared with those in which no pregnancy was established (Mendoza et al., 2002; Baka and Malamitsi-Puchner, 2006). Detectable serum concentrations of IL-1β were associated...
with a higher implantation rate in IVF–embryo transfer patients (Karagouni et al., 1998). Leal et al. (2006) found differences in the concentrations of IL-1β in FF associated with a lack of pregnancy after excluding patients with endometriosis (Leal et al., 2006). IL-6 is a regulator of inflammation and immunity, which may represent a physiological link between the endocrine and the immune systems. IL-6 is produced by rat and bovine granulosa cells in vitro (Gorospe et al., 1992; Gorospe and Spangelo, 1993; Alpizar and Spicer, 1994). IL-6 can influence steroidogenesis and granulosa cell steroidogenesis (Adashi, 1990).

IL-6 and IL-1 may act on early and late stages of normal B lymphocyte differentiation, and their synergistic effect is potentiated by glucocorticosteroids (Emilie et al., 1988). Immunohistochemical studies on human oocytes show IL-6 secretion in corpora lutea and theca cells, and its bioactivity has been detected in FF of IVF patients (Baes et al., 1987; Spangelo et al., 1989). No significant difference between FF IL-6 concentrations of low- and high-responder intracytoplasmic sperm injection (ICSI) patients was detected (Hammadeh et al., 2003).

IL-12 is produced by B-cells, phagocytic cells, and other antigen-presenting cells (Sartori et al., 1997). The promotion of production of a potent natural killer (NK) activator, interferon-γ (IFN-γ) by IL-12 is responsible for regulating abortion in mice (Hayakawa et al., 1999). The correlation between FF and/or serum concentrations of IL-12 and negative IVF outcome ranged from studies showing a strong association to studies showing no association at all (Gazvani et al., 2006). So far as is known, none of the studies in this regard has established a connection between FF cytokines and oocyte recruitment and maturity. The objective of this study was to investigate the role of FF cytokines in relation to oocyte recruitment and maturity as well as IVF outcome.

Materials and methods

The study was approved by the Institutional Review Board (IRB) of the Cleveland Clinic. Follicular fluid was collected from 112 patients undergoing 112 consecutive IVF cycles over a 12-month period. Fifty patients underwent conventional IVF cycles and 62 patients underwent ICSI. There were 31 endometriosis patients, 15 patients who underwent embryo transfer patients were scheduled between 12:00 and 14:00 hours, 3 or 5 days after embryo evaluation and before embryo transfer. Embryo transfers were scheduled between 12:00 and 14:00 hours, 3 or 5 days after oocyte retrieval.

Ovarian stimulation

The study was approved by the Institutional Review Board (IRB) of the Cleveland Clinic. Follicular fluid was collected from 112 patients undergoing 112 consecutive IVF cycles over a 12-month period. Fifty patients underwent conventional IVF cycles and 62 patients underwent ICSI. There were 31 endometriosis patients, 15 idiopathic infertility, 21 tubal factor infertility, 15 ovulatory factor infertility, and 30 with male factor infertility. Patients with blood contaminated FF were excluded. Those who were included were divided into two groups: those who achieved pregnancy and those who did not.

Ovarian stimulation

The long down-regulation protocol (Lupron; Tap Pharmaceutical Inc., Deerfield, IL, USA) was used in all patients as a daily subcutaneous (s.c.) dose of 10 IU (0.5 mg) started on cycle day 21. Once serum oestradiol concentrations were suppressed to ≤50 pg/ml, the dose was reduced to 5 IU (0.25 mg) and continued until the day of human chorionic gonadotrophin (HCG) administration. Ovarian stimulation with recombinant FSH (Gonal-f, Serono, Randolph, MA, USA), urinary FSH (Metrodin, Serono) or human menopausal gonadotrophin (Humegon, Organon, West Orange, NJ, USA) was begun following pituitary down-regulation. The standard initial dose was 300 IU starting on day 3 of the treatment cycle. The selection of the ovarian stimulation regimen was individualized based on the results of the ovarian reserve screening.

The ovarian response was monitored by serial serum oestradiol concentrations and transvaginal ultrasonograms beginning on day 5 of stimulation until the day of HCG administration. Based on these results, the FSH dose and subsequent monitoring was individualized. Ovarian stimulation was continued until at least two follicles reached a mean diameter of ≥18 mm, at which time HCG (Profasi; Serono) 10,000 IU s.c. was administered, 36 h before oocyte recovery.

Sperm collection and preparation

Semen samples were obtained by masturbation concurrently with oocyte retrieval following 3–5 days of abstinence. Spermatozoa were prepared by a density gradient centrifugation technique. Samples were loaded onto a single 90% ISolate (Irvine Scientific) layer and centrifuged at 300 g for 20 min at room temperature. The resulting pellet was washed by centrifugation for an additional 7 min and re-suspended in HTF media supplemented with 5% synthetic serum substitute (SSS; Irvine Scientific) at 37°C under 5% CO₂, 5% O₂ and 90% N₂.

Gamete and embryo culture

After cumulus dissection and washing, the oocytes were placed in 1 ml of HTF supplemented with 5% SSS. Fertilization was confirmed 14–16 h post-insemination by the presence of two pronuclei (2PN) and extrusion of the second polar body. Normally fertilized oocytes were cultured in groups of four or five in 1 ml of HTF with SSS until the early afternoon of day 3. Following a five drop rinse in blastocyst medium (Irvine Scientific), they were then placed in 1 ml of in the same medium. A second change over to fresh blastocyst medium was done on the morning of day 5 after embryo evaluation and before embryo transfer. Embryo transfers were scheduled between 12:00 and 14:00 hours, 3 or 5 days after oocyte retrieval.

Embryo evaluation

Day 3 and day 5 embryos were evaluated with an Olympus X70 inverted microscope (×600; OlympusAmerica, Melville,NY,USA), equipped with Hoffman Modulation Optics (Narishige, Tokyo, Japan). Cell number, degree (%) and pattern of fragmentation were recorded on day 3. The degree of fragmentation was defined as the embryonic volume occupied by enucleated cytoplasmic fragment.
Development on day 5 was recorded as follows. A distinct inner cell mass (ICM), organized as a compacted mass of cells, or a cohesive layer of numerous tightly packed cells in the trophectoderm (TE) were considered normal. Highly irregular ICM and/or TE cells on days 5 and 6 were considered abnormal and arrested.

**Preparation of the follicular fluid**

Follicular fluid was aspirated from the follicles on the day of oocyte retrieval. The cellular constituents of the FF were removed by centrifugation at 300 g for 20 min. Follicular fluid supernatants were then collected and stored in aliquots at −70°C until the cytokine concentrations were determined.

**Detection of cytokines in follicular fluid**

Commercially available, cytokine-specific, enzyme-linked immunosorbent assays (ELISA; R and D Systems Inc., Minneapolis, MN, USA) were used to measure the concentrations of IL-1β (kit number DLB50), IL-12 (whole, kit number D1200), IL-6 (kit number D6050), IL-13 (kit number D1300), and TNFα (kit number DTA00C) in the FF. The frozen samples were thawed and analysed. Samples from each patient group were always measured in parallel and in duplicate to avoid inter-assay variance. The samples were pooled per patient. The sensitivities of the IL-1β, IL-12, IL-6, IL-13, and TNFα ELISA were 1, 0.7, 5, 32, and 4.4 pg/ml respectively with standard curve ranges of 3.9–250, 3.12–300, 7.8–500, 62.5–4000, and 15.6–1000 pg/ml respectively. The intra-assay and inter-assay coefficients of variation were: for IL-1β, 2.8–8.5 and 4.1–8.4 pg/ml; for IL-12, 1.1–1.5 and 3.3–7.1 pg/ml; for IL-6, 2.0–4.2 and 3.3–6.4 pg/ml; for IL-13, 2.4–6.3 and 3.8–6.5 pg/ml; and for TNFα, 4.2–5.2 and 4.6–7.4 pg/ml.

**Statistical analysis**

The demographic variables and FF measurements were compared across the patient groups with Kruskal–Wallis tests. Pairwise comparisons between the groups were performed with the Wilcoxon’s rank sum test. Results of these analyses are reported using the median and interquartile range (IQR: 25th to 75th percentile). Statistical computations were performed with SAS version 8.1 (SAS Institute, Cary, NC, USA), and statistical significance was assessed using two-tailed tests and an alpha level of \( P < 0.05 \).

**Results**

**Demographic variables and assessment of cycle outcome**

Fifty-two patients (46%) achieved pregnancy, whereas 60 (54%) did not. The demographic features of the study population and the indications for assisted reproduction are presented in Table 1. A total of 112 patients underwent 112 cycles of IVF throughout the duration of the study. The patients’ ages, parity and percentage of primary versus secondary infertility were similar between groups of pregnant and non-pregnant cycles. There were no significant differences in days of stimulation, number of FSH ampoules or amount of FSH used (IU) between the groups (Table 2). Serum concentrations of day 3 FSH, day 7 LH, day 3, day 7, and day 10 oestradiol (pg/ml) as well as oestradiol on day of HCG administration (pg/ml) were similar between pregnant and non-pregnant cycles. The number of mature follicles

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Non-pregnant cycles</th>
<th>Pregnant cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>60</td>
<td>52</td>
</tr>
<tr>
<td>No. of cycles</td>
<td>60</td>
<td>52</td>
</tr>
<tr>
<td>Mean age (years) ± SD</td>
<td>34.17 ± 4.25</td>
<td>33.6 ± 3.56</td>
</tr>
<tr>
<td>Mean parity ± SD</td>
<td>0.4 ± 0.5</td>
<td>0.3 ± 0.5</td>
</tr>
<tr>
<td>No. with secondary infertility (%)</td>
<td>26 (43)</td>
<td>27 (52)</td>
</tr>
<tr>
<td>No. with primary infertility (%)</td>
<td>34 (57)</td>
<td>25 (48)</td>
</tr>
<tr>
<td>Infertility factor n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>17 (28)</td>
<td>13 (25)</td>
</tr>
<tr>
<td>Tubal</td>
<td>10 (17)</td>
<td>11 (21)</td>
</tr>
<tr>
<td>Ovarian</td>
<td>8 (13)</td>
<td>7 (13)</td>
</tr>
<tr>
<td>Endometriosis</td>
<td>18 (30)</td>
<td>13 (25)</td>
</tr>
<tr>
<td>Unexplained</td>
<td>7 (12)</td>
<td>8 (15)</td>
</tr>
</tbody>
</table>

There were no statistically significant differences between the two groups.
on day of HCG administration and oocytes retrieved were also similar between the two groups. The number of oocytes injected in the ICSI group was apparently higher among the non-pregnant group, but not significantly.

There were no significant differences in fertilization rate, number of arrested embryos, frozen 2PN stage embryos, frozen blastocysts and embryos transferred between the groups (Table 2).

**Follicular fluid cytokines**

Interleukin-13 and TNFα were not detected in the peri-ovulatory FF of any patient. Concentrations of IL-12 (pg/ml) were significantly lower among pregnant cycles than in the non-pregnant cycle group (P = 0.0002). Concentrations of FF IL-6 were significantly higher in pregnant compared with non-pregnant cycles (P = 0.0005). Although concentrations of FF interleukin-1β (pg/ml) and tumour necrosis factor TNFα (pg/ml) were higher among the pregnant group, these differences were not significant (Table 2).

**Discussion**

The role of FF interleukins as biological markers for IVF outcome is gaining increasing attention in the literature. Herriot *et al.* found neutrophil chemotactic activity in pre-ovulatory FF to be higher in conception than in non-conception cycles (Herriot *et al.*, 1986). IL-12 is involved in induction and maintenance of the immune response (Lamont and Adorini, 1996). Vujisic *et al.* suggested a role of IL-12 in human reproduction, and confirmed the presence of the p40 subunit of IL-12 in human FF from women undergoing natural cycle IVF and embryo transfer (Vujisic *et al.*, 2004).

The present study found significantly (P = 0.0002) higher concentrations of IL-12 in the peri-ovulatory FF of women who failed to become pregnant with IVF, consistent with the results reported by Gazvani *et al.* (2000). These workers attributed this to follicle immaturity, as well as negative effects of IL-12 on folliculogenesis, oocyte quality, and/or implantation. IL-12 is important in the initiation of T helper (Th)-1 response that is detrimental to implantation and, indirectly, in down-regulation of a Th-2 response that is associated with successful pregnancy. The anti-angiogenic properties of IL-12 and its down-regulating effects on Th-2 response may be the underlying cause of impaired implantation (Gazvani *et al.*, 2000). Ledeé-Bataille *et al.* (2004) suggested that IL-12 is an abortifacient because it induces production of IFN-γ, a potent NK activator (Ledeé-Bataille *et al.*, 2004).

The present study also noted that IL-6 was significantly (P = 0.0005) higher in the pregnant compared with the non-pregnant cycles. It has been suggested that IL-6 significantly inhibited HCG-induced progesterone secretion of granulosa lutein cells which could compromise endometrial receptivity (Kawasaki *et al.*, 2003). It is concluded that higher concentrations of IL-12 and lower concentrations of IL-6 in the peri-ovulatory FF appear to be associated with a negative outcome in IVF treatment. Both cytokines are powerful biological markers that may influence IVF outcome through an effect on oocyte quality and/or implantation.
Acknowledgements

Research support provided by the Research Programs Committee, Cleveland Clinic Foundation.

References


Giuliani A, Mitterhammer H, Burda A et al. 2004 Polymorphonuclear leukocyte function during the menstrual cycle and during controlled ovarian hyperstimulation. Fertility and Sterility 82, 1711–1713.


Hayakawa S, Nagai N, Kanaeda T et al. 1999 Interleukin-12 augments cytolytic activity of peripheral and decidual lymphocytes against choriocarcinoma cell lines and primary culture human placental trophoblasts. American Journal of Reproductive Immunology 41, 320–329.


Karagouni EE, Chryssikopoulos A, Mantzavinos T et al. 1998 Interleukin-1beta and interleukin-1alpha may affect the implantation rate of patients undergoing in vitro fertilization-embryo transfer. Fertility and Sterility 70, 553–559.


Leal A, Morales A, Gonza ‘lez E et al. 2006 Measurement in serum and follicular fluid of interleukin 1 beta and interleukin 12 to predict outcome in patients ongoing IVF program. Fertility and Sterility 86, S490-S491


Presented in part at the 60th Annual Meeting of the American Society for Reproductive Medicine, 2004, October 16–20, Philadelphia, PA, USA.

Received 23 April 2007; refereed 14 May 2007; accepted 21 May 2007.